Grifols (GIKLY) Common Equity (2009 - 2025)
Grifols (GIKLY) posted Common Equity of $8.9 billion for Q4 2025, down 3.76% quarter-over-quarter from $9.2 billion in Q4 2024, and down 3.76% year-on-year from $9.2 billion in Q4 2024.
Grifols (GIKLY) Common Equity (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Common Equity for 16 consecutive years, with $8.9 billion the latest figure, recorded in Q4 2025.
- Common Equity for Q4 2025 came in at $8.9 billion, down 3.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.9 billion (down 3.76% YoY), and the FY2025 annual result was $8.9 billion, up 31707.94% from the prior year.
- Common Equity was $8.9 billion for Q4 2025 at Grifols, down from $9.2 billion in the prior quarter.
- Over five years, Common Equity peaked at $9.2 billion in Q4 2024 and troughed at $7.8 billion in Q4 2021.
- Average Common Equity over 5 years is $8.4 billion, with a median of $8.1 billion recorded in 2022.
- Year-over-year, Common Equity surged 1539.99% in 2021 and slipped 3.76% in 2025.
- Over 5 years, Common Equity stood at $7.8 billion in 2021, then rose by 3.73% to $8.1 billion in 2022, then declined by 0.68% to $8.1 billion in 2023, then gained by 13.77% to $9.2 billion in 2024, then retreated by 3.76% to $8.9 billion in 2025.
- Per Business Quant data, the three most recent Common Equity figures were $8.9 billion in Q4 2025, $9.2 billion in Q4 2024, and $8.1 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 31.20 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 81.19 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -6.61 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.38 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 8.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.85 Bn |
| Dec 31, 2024 | 9.20 Bn |
| Dec 31, 2023 | 8.08 Bn |
| Dec 31, 2022 | 8.14 Bn |
| Dec 31, 2021 | 7.85 Bn |
| Dec 31, 2020 | -544.88 Mn |
| Sep 30, 2020 | 8.30 Bn |
| Mar 31, 2020 | 7.96 Bn |
| Dec 31, 2019 | 7.58 Bn |
| Sep 30, 2019 | 5.89 Bn |
| Dec 31, 2018 | 5.36 Bn |
| Sep 30, 2018 | 4.82 Bn |
| Jun 30, 2018 | 4.74 Bn |
| Mar 31, 2018 | 5.99 Bn |
| Dec 31, 2017 | 4.28 Bn |
| Jun 30, 2017 | 3.94 Bn |
| Dec 31, 2016 | 4.03 Bn |
| Sep 30, 2016 | 3.94 Bn |
| Jun 30, 2016 | 3.86 Bn |
| Mar 31, 2016 | 3.64 Bn |